Kiora Pharmaceuticals
KPRX
7 hedge funds and large institutions have $825K invested in Kiora Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
43% more capital invested
Capital invested by funds: $575K → $825K (+$250K)
40% more funds holding
Funds holding: 5 → 7 (+2)
0% less ownership
Funds ownership: 0% → 0% (-0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$247K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$67.3K |
| 3 |
BlackRock
New York
|
+$22.4K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$22.4K |
| 5 |
FPF
FNY Partners Fund
New York
|
+$11.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$314K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $626K | +$247K | +22 | +96% |
|
|
VKH
2
Virtu KCG Holdings
New York
| $77K | +$67.3K | +6 | New |
|
|
IA
3
IFP Advisors
Tampa,
Florida
| $35K | – | – | – |
|
|
4
BlackRock
New York
| $28K | +$22.4K | +2 | New |
|
|
TSS
5
Two Sigma Securities
New York
| $26K | +$22.4K | +2 | New |
|
|
VIA
6
Vantage Investment Advisors
State College,
Pennsylvania
| $17K | – | – | – |
|
|
FPF
7
FNY Partners Fund
New York
| $8K | +$11.2K | +1 | New |
|
8
Morgan Stanley
New York
| $3K | – | – | – |
|
9
Bank of America
Charlotte,
North Carolina
| $1K | – | – | – |
|
10
Creative Planning
Overland Park,
Kansas
| $1K | – | – | – |
|
11
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $1K | – | – | – |
|
|
LTFS
12
Ladenburg Thalmann Financial Services
Miami,
Florida
| $1K | – | – | – |
|
|
TRCT
13
Tower Research Capital (TRC)
New York
| $1K | – | – | – |
|
|
SM
14
Sabby Management
Miami Beach,
Florida
| – | -$314K | -36 | Closed |
|
|
15
UBS Group
Zurich,
Switzerland
| – | -$4K | – | – |
|
KPRX Hedge Fund Activity: Q1 2017 in Review
7 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Kiora Pharmaceuticals (KPRX) for Q1 2017, worth a combined $825K — up 43% from $575K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new KPRX positions and 1 closed out — a net gain of 3 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Vanguard Group, adding an estimated $247K. The largest seller was Sabby Management, exiting entirely with an estimated $314K sold.
- 7 institutional investors held Kiora Pharmaceuticals (KPRX) as of Q1 2017, up from 5 in Q4 2016.
- Funds reported $825K of Kiora Pharmaceuticals stock for Q1 2017, up 43% quarter-over-quarter.
- 4 funds opened new Kiora Pharmaceuticals positions in Q1 2017 and 1 closed out, a net change of +3 holders.
- The largest Kiora Pharmaceuticals buyer in Q1 2017 was Vanguard Group, an estimated $247K added.
- The largest Kiora Pharmaceuticals seller in Q1 2017 was Sabby Management, an estimated $314K sold.
Based on aggregated 13F filings for Q1 2017.